Abcam, ab281361, Human CD791 knockout Raji cell lysate

Size: 1Kit
CD79A KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included.
Key facts
Cell type:Raji,
Species or organism:Human,
Tissue:Lymphatic,
Knockout validation:Next Generation Sequencing,Western blot,
Disease:Lymphoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-CD79A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD79a also known as Ig-alpha or MB-1 is a component of the B cell antigen receptor (BCR) complex. It is a transmembrane protein with a molecular mass of approximately 47 kDa. CD79a is part of a heterodimer with CD79b and is mainly expressed on the surface of B lymphocytes. This protein plays a critical mechanical role in signaling transduction through the BCR by associating with membrane-bound immunoglobulin molecules helping to initiate the immune response upon antigen binding.
Biological function summary
This protein acts as an essential mediator in the immune system. CD79a together with CD79b forms part of the BCR complex critical for B cell development and maturation. The BCR complex activates signaling cascades that influence B cell fate decisions such as proliferation differentiation and apoptosis. By transmitting signals from the BCR CD79a helps regulate these cellular functions necessary for efficient immune defense.
Pathways
CD79a plays a pivotal role in the B cell receptor signaling pathway. This pathway involves signaling molecules such as spleen tyrosine kinase (SYK) and phosphoinositide 3-kinase (PI3K) which are activated upon BCR engagement. CD79a acts in concert with other proteins including CD79b and the IgM receptor facilitating downstream signaling cascades that ensure proper B cell responses. Its role is important for linking extracellular antigen recognition to intracellular signaling events.
CD79a is significant in conditions like B cell lymphomas and certain immunodeficiencies. Abnormal expression or mutations in CD79a are associated with some types of non-Hodgkin lymphoma. The protein's interaction with CD79b is particularly relevant as alterations in these proteins' function or expression can impact B cell development and lead to pathogenesis in lymphoproliferative disorders. Consequently CD79a serves as an important biomarker and potential therapeutic target in these diseases.